Bioengineering,
Год журнала:
2022,
Номер
9(7), С. 294 - 294
Опубликована: Июнь 30, 2022
Currently,
breast-cancer
treatment
has
a
number
of
adverse
side
effects
and
is
associated
with
poor
rates
progression-free
survival.
Therefore,
radiolabeled
anti-EpCAM
targeted
biomimetic
coated
nanocarrier
(EINP)
was
developed
in
this
study
to
overcome
some
the
challenges.
The
double
emulsion
method
synthesized
poly(lactic-co-glycolic
acid)
(PLGA)
nanoparticle
Na131I
entrapped
core.
PLGA
human
red
blood
cell
membranes
labeled
epithelial
adhesion
molecule
(EpCAM)
antibody
enable
it
target
EpCAM
overexpression
by
cells.
Characterization
determined
EINP
size
as
295
nm,
zeta
potential
−35.9
mV,
polydispersity
0.297.
radiochemical
purity
>95%.
Results
efficacy
against
positive
MCF-7
breast
cancer
at
24,
48,
72
h
were
69.11%,
77.84%,
74.6%,
respectively,
demonstrating
that
EINPs
achieved
greater
cytotoxic
supported
NIS-mediated
uptake
than
non-targeted
131INPs
Na131I.
In
comparison,
fibroblast
(EpCAM
negative)
treated
had
significantly
lower
cytotoxicity
(p
<
0.05).
Flow
cytometry
fluorescence
imaging
visually
signified
delivery
specifically
cells
result
targeting.
Additionally,
favorable
safety
profile,
hemolysis.
Journal of Drug Delivery Science and Technology,
Год журнала:
2023,
Номер
91, С. 104904 - 104904
Опубликована: Сен. 1, 2023
SN-38,
recognized
as
the
primary
active
derivative
of
pivotal
chemotherapeutic
agent
CPT-11,
demonstrates
substantially
enhanced
efficacy
in
colorectal
cancer
(CRC)
management
compared
to
CPT-11.
Nonetheless,
challenges
such
low
stability,
inadequate
aqueous
solubility,
limited
bioavailability,
and
non-specific
targeting
cells
hinder
its
clinical
adoption.
In
present
research,
we
synthesized
SN-38-loaded
liposomes
cloaked
with
macrophage
membranes
(SN-38@MM-LPs)
assess
their
therapeutic
potential
safety
profile
addressing
CRC.
SN-38@MM-LPs
were
using
an
incubation
extrusion
technique,
combining
a
membrane
(LPs).
It
was
characterized
by
size,
zeta
potential,
transmission
electron
microscopy
observations,
polydispersity
index
coomassie
bright
blue
staining.
CCK-8,
EdU,
flow
cytometry
assays
performed
evaluate
viability
apoptosis
rates
HCT116
HCT8
after
treatment
SN-38@MM-LPs.
A
cellular
uptake
assay
conducted
internalization
vitro.
Moreover,
biodistribution,
efficacy,
further
assessed
orthotopic
xenograft
model
mice.
Characterization
results
revealed
that
possess
spherical
morphology
consistent
size
distribution
(129
nm)
drug
loading
efficiency
5.54
±
0.73%.
SN-38
curtailed
growth
promoted
both
cells.
The
impact
accentuated
when
delivered
via
SN-38@LPs
Notably,
model,
manifested
superior
tumor-targeting
capabilities
outcomes.
Additionally,
presented
negligible
hepatic
toxicity.
showcased
potent
targeted
antitumor
actions
Consequently,
emerge
nanoparticle
formulation
could
amplify
simultaneously
mitigating
liver
toxicity
concerns.
Abstract
Albumin,
as
a
natural
polymer,
offers
the
advantages
of
non‐toxicity,
degradability,
and
biocompatibility.
It
is
widely
used
in
formulating
nanomedicines
for
cancer
treatment.
In
this
review,
we
introduce
methods
drawbacks
albumin
nanoparticles
when
utilized
drug
carrier.
We
summarize
treatment,
discuss
surface
modification
such
gold
magnetic
by
coating
functional
group,
focus
on
new
properties
imparted
vitro
prefabrication
protein
crowns.
Additionally,
elaborate
application
vaccines.
Finally,
challenges
future
trends
albumin‐based
nanodrugs
therapy
are
presented.
Bioengineering,
Год журнала:
2022,
Номер
9(7), С. 294 - 294
Опубликована: Июнь 30, 2022
Currently,
breast-cancer
treatment
has
a
number
of
adverse
side
effects
and
is
associated
with
poor
rates
progression-free
survival.
Therefore,
radiolabeled
anti-EpCAM
targeted
biomimetic
coated
nanocarrier
(EINP)
was
developed
in
this
study
to
overcome
some
the
challenges.
The
double
emulsion
method
synthesized
poly(lactic-co-glycolic
acid)
(PLGA)
nanoparticle
Na131I
entrapped
core.
PLGA
human
red
blood
cell
membranes
labeled
epithelial
adhesion
molecule
(EpCAM)
antibody
enable
it
target
EpCAM
overexpression
by
cells.
Characterization
determined
EINP
size
as
295
nm,
zeta
potential
−35.9
mV,
polydispersity
0.297.
radiochemical
purity
>95%.
Results
efficacy
against
positive
MCF-7
breast
cancer
at
24,
48,
72
h
were
69.11%,
77.84%,
74.6%,
respectively,
demonstrating
that
EINPs
achieved
greater
cytotoxic
supported
NIS-mediated
uptake
than
non-targeted
131INPs
Na131I.
In
comparison,
fibroblast
(EpCAM
negative)
treated
had
significantly
lower
cytotoxicity
(p
<
0.05).
Flow
cytometry
fluorescence
imaging
visually
signified
delivery
specifically
cells
result
targeting.
Additionally,
favorable
safety
profile,
hemolysis.
